

Consumer Medicine Information**WARNING: SERIOUS MENINGOCOCCAL INFECTIONS**

As Zilbrysq inhibits the body's natural defences against infection, its use may increase your risk of infections caused by *Neisseria meningitidis*, such as meningococcal infection (severe infection of the linings of the brain and spinal cord and/or an infection of the blood) and also of other infections caused by *Neisseria* bacteria, such as gonorrhea.

These infections require urgent and appropriate care as they may become rapidly serious or fatal, or lead to major disabilities. It is important to understand the precautions to take to reduce the risk of these infections and what to do if you are worried you may have an infection (see "What I should know before I use Zilbrysq" below or refer to your Patient Alert Card).

- You must be vaccinated against meningococcal infection before starting Zilbrysq.
- If you initiate Zilbrysq treatment less than 2 weeks after receiving a meningococcal vaccine you must take antibiotics until 2 weeks after you have been vaccinated to reduce the risk of meningococcal infection.
- You need to be aware of the signs and symptoms of meningococcal infection (see "What should know before I use Zilbrysq" below or refer to your Patient Alert Card) and notify your doctor immediately if any of the symptoms occur. If you cannot reach your doctor, go to the Emergency Department at your nearest hospital. Show your Patient Alert Card to any doctor or nurse who treats you.

This leaflet provides important information about using Zilbrysq. **You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Zilbrysq.**

Where to find information in this leaflet:

1. Why am I using Zilbrysq?
2. What should I know before I use Zilbrysq?
3. What if I am taking other medicines?
4. How do I use Zilbrysq?
5. What should I know while using Zilbrysq?
6. Are there any side effects?
7. Product details

1. Why am I using Zilbrysq

Zilbrysq contains the active ingredient zilucoplan tetrasodium. Zilbrysq is a selective immunosuppressant. Zilucoplan binds to and inhibits a specific protein in the body that causes inflammation, preventing your body's systems from attacking and destroying connections between nerves and muscles.

Zilbrysq is used to treat generalised myasthenia gravis by blocking the body's inflammatory response. Myasthenia gravis can lead to intense muscle weakness, extreme fatigue, difficulty breathing, difficulty with moving and activities of daily living.